Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We dispute whether the detection of EWSR1-FEV mandates one to diagnose the patient's tumor as a member of the Ewing sarcoma family.
|
31831298 |
2020 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Conversely, treatment with the FAK inhibitor Y15 enhanced caspase-mediated apoptosis and EwS cell migration, independent from the respective EWSR1-ETS fusion type, mimicking an anoikis-like phenotype and paralleling the effects of FAK siRNA knockdown.
|
31811703 |
2020 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tumors had a similar morphologic appearance and immunophenotype as ES with more common EWSR1-ETS fusions.
|
31756779 |
2020 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma (ES) family of tumors includes bone and soft tissue tumors that are often characterized by a specific translocation between chromosome 11 and 22, resulting in the EWS-FLI1 fusion gene.
|
31275859 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
EWS-FLI1, the oncogenic driver of Ewing sarcoma, regulated LDH A (LDHA) expression.
|
31431459 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ewing Sarcoma (ES) is characterized by recurrent translocations between EWSR1 and members of the ETS family of transcription factors.
|
31550266 |
2019 |
Ewings sarcoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Through integrative analysis, we identify MEIS1 as a super-enhancer-driven oncogene, which co-operates with EWS-FLI1 in transcriptional regulation, and plays a key pro-survival role in Ewing sarcoma.
|
30496486 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Emerging studies of Ewing sarcoma have demonstrated EWS-FLI1-driven chromatin remodeling as a key aspect of tumorigenicity.
|
31207107 |
2019 |
Ewings sarcoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that EWS-FLI1 increases BCL-2 expression; however, inhibition of BCL-2 alone by venetoclax is insufficient to sensitize Ewing sarcoma cells to olaparib, revealing a dual necessity for BCL-2 and BCL-X<sub>L</sub> in Ewing sarcoma survival.
|
30348635 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
|
30470587 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma is characterized by a pathognomonic chromosomal translocation that generates the EWSR1-FLI1 chimeric transcription factor.
|
31036566 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This interaction has functional consequences in Ewing sarcoma (ES), childhood and adolescence bone malignancies driven by fusions between EWSR1 and FLI1.
|
31577941 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings show that MSCs from anatomically distinct sites are differentially susceptible to EWS-FLI1-induced transformation, supporting the premise that the dominant presentation of Ewing sarcoma in pelvic and stylopod bones is attributable to anatomically-defined differences in MSCs.
|
30845695 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
EWSR1 (Ewing Sarcoma breakpoint region 1/EWS RNA binding protein 1) gene is ubiquitously expressed in most cell types, indicating it has diverse roles in various cellular processes and organ development.
|
30481590 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Despite these similarities, Ewing-like sarcomas lack the pathognomonic molecular hallmark of Ewing sarcoma: A translocation between a gene of the RNA-binding TET family (EWSR1 or FUS) with a gene of the ETS-transcription family ( FLI1, ERG, ETV1, ETV4, or FEV).
|
30257034 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In recent years, a novel small round cell sarcoma harboring EWSR1-NFATC2 translocation with immunomorphologic overlap with Ewing sarcoma (ES), myoepithelial tumors, and extraskeletal myxoid chondrosarcoma has emerged.
|
30994538 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings illustrate that modulation of the alternative splicing of <i>EWS-FLI1</i> pre-mRNA is a novel strategy for future therapeutics against the <i>EWSR1</i> exon 8 containing fusion oncogenes present in a third of Ewing sarcoma.
|
31511320 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have identified a direct connection between the EWS-FLI1 protein and ARID1A isoform protein variant ARID1A-L. We demonstrate here that ARID1A-L is critical for ES maintenance and supports oncogenic transformation.
|
31392992 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings not only provide novel insights into the importance of the N-terminal EWSR1 domain for regulation of fusion protein stability, but also indicate that inhibition of deubiquitinating enzyme(s) might constitute a novel therapeutic strategy in treatment of Ewing sarcoma.
|
30700749 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Certain bone and soft tissue (BST) tumours harbour a chromosomal translocation [t(6;22)(p21;q12)], which fuses the Ewing's sarcoma (EWS) gene at 22q12 with the octamer-binding transcription factor 4 (Oct-4) gene at 6p21, resulting in the chimeric EWS-Oct-4 protein that possesses high transactivation ability.
|
31155838 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PET-CT imaging features that differentiate between positive and negative EWSR1 translocation in Ewing sarcoma.
|
31107830 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Next, the Ewing sarcoma tumour is found to have EWSR1 (exon 10)-FLI1 (exon 8) translocation based on NGS.
|
30819134 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibitors of the bromodomain and extra-terminal domain (BET) family proteins modulate EWS-FLI1 activities in Ewing sarcoma.
|
30926641 |
2019 |
Ewings sarcoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Results were compared to methylation data of 30 EwS with various EWSR1-ETS fusions and one EwS with FUS-ERG fusion, 16 URCS with CIC rearrangement and 10 URCS with BCOR alteration and a total of 81 EWSR1-associated soft tissue sarcomas including 7 angiomatoid fibrous histiocytomas, 7 clear cell sarcomas of the soft tissue, 28 desmoplastic small round cell tumors, 10 extraskeletal myxoid chondrosarcomas and 29 myxoid liposarcomas.
|
30895378 |
2019 |
Ewings sarcoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our previous in silico drug screening identified entinostat as a drug hit that was predicted to reverse the ES disease signatures and EWS-FLI1-mediated gene signatures.
|
31025088 |
2019 |